Repligen to acquire Avitide for ~$150M in cash and stock, adding affinity chromatography capabilities

REPLIGEN CORP

Total consideration ~$150M, consisting of $75M cash and $75M in Repligen common stock, plus three-year earnout.
Avitide expected to contribute ~$10M revenue in 2022 and be accretive to adjusted EPS in 2023.
Transaction strengthens Repligen's affinity ligand discovery platform for gene therapy and other modalities.
Deal expected to close in Q3 2021; funded with cash on hand ($734M at June 30, 2021).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.